Neurogene Inc. reported $0 of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $0 (to Q4 2025). Net income: −$111M, trailing twelve months to Q2 2026. Free cash flow: −$88M, trailing twelve months to Q2 2026. EPS: −$5.04, trailing twelve months to Q2 2026.

NGNENeurogene Inc.

Healthcare

$26.44+13% 1Y

$26.44

$16.3752 weeks$42.88

NGNE as reported

Neurogene Inc. reported $0 of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

Revenue, trailing twelve months · to Q4 2025 · every figure below is as filed, with no scoring applied

Net income: −$111M
Net income · +32% year on year · trailing twelve months to Q2 2026
Free cash flow: −$88M
Free cash flow · +18% year on year · trailing twelve months to Q2 2026
EPS: −$5.04
EPS · +17% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for NGNE, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$0	n/a	Q4 2025
Net income	−$111M	+32%	Q2 2026
EPS	−$5.04	+17%	Q2 2026
Operating margin	−1388%	n/a	Q3 2023 · 11 quarters behind
Net margin	−1315%	n/a	Q3 2023 · 11 quarters behind
ROE	−40%	n/a	Q2 2026
ROA	−36%	n/a	Q2 2026
Free cash flow	−$88M	+18%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.